Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydroquinone + tretinoin is a topical pharmaceutical combination used primarily for the treatment of **hyperpigmentation disorders** such as melasma, post-inflammatory hyperpigmentation, age spots, and freckles. **Hydroquinone** is a skin-lightening agent that works by inhibiting *tyrosinase*, the key enzyme in melanin synthesis, thus reducing pigment production and fading dark spots. **Tretinoin** is a synthetic retinoid (vitamin A derivative) that normalizes keratinization, stimulates skin cell turnover, and increases epidermal regeneration, thereby aiding even skin tone and texture. It also enhances the penetration and efficacy of hydroquinone. The combination is typically prescribed as either compounded formulations or as separate creams, and is usually applied topically to affected areas under medical supervision. Prolonged usage of hydroquinone is not recommended due to risks such as ochronosis and contact dermatitis. The combination may also synergize with corticosteroids (as in triple therapy formulas) to mitigate irritation and inflammation[1][2][3][8][12].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydroquinone + tretinoin.